combining immunotherapies: inhibiting the ctla-4 and pd-1 pathways
Published 9 years ago • 2.2K plays • Length 7:37Download video MP4
Download video MP3
Similar videos
-
5:58
ctla4 and attenuation of t cell response
-
1:54
two main pathways involved in immunotherapy pd 1 and ctla4
-
6:13
anti-pd-1 or anti-ctla-4 in first line therapy?
-
2:07
immune checkpoint inhibitors, the next generation cancer therapy - creative biolabs
-
2:19
combining ctla-4 agents with pd-1/pd-l1 agents in lung cancer
-
1:16
explaining immunotherapy, pd-l1 and pd-1
-
1:23
exploring the combination anti-ctla-4 and anti-pd-1 in multiple myeloma post-transplant
-
9:02
pd1/ ctla4 : upfront or sequentially?
-
50:03
arlene sharpe: roles of the pd-1 pathway in controlling tolerance & tumor immunity
-
2:12
cancer immunotherapy | the pd-l1 pathway
-
3:20
update in anti-ctla4 and anti-pd1 treatment in advanced melanoma
-
1:37
dr. adams on the utility of combination ctla-4 and pd-1 blockade in breast cancer
-
4:47
checkmate 227: combining ctla-4 and pd-l1 in nsclc
-
25:34
novel immunotherapies and combinations
-
2:35
beyond anti-pd-1 and anti-ctla-4 in melanoma
-
5:33
cancer immune checkpoint inhibitors
-
1:37
dr. hammers discusses combining ido and pd-1 inhibitors in rcc
-
0:49
pd-1 and pd-l1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, c... | rtcl.tv
-
4:10
combination of medi0680, an anti-pd-1 antibody, with durvalumab, an anti-pd-l1 antibody